◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

Home › All stocks › ILMN

Illumina Inc (ILMN) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DIAGNOSTICS & RESEARCH · DATA UPDATED 2026-07-23

Illumina Inc (ILMN) operates in the DIAGNOSTICS & RESEARCH industry and is headquartered in San Diego, United States with about 8,600 employees. Its market capitalization is roughly $29 billion. In the fiscal year ended 2025-12-31, ILMN reported $4.3B in revenue and $850M in net income.

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.

Interactive charts & full statements → Open the ILMN valuation workbench →

ILMN Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$4.4B	$4.3B	$4.4B	$4.5B	$4.6B	$4.5B	$3.2B	$3.5B	$3.3B	$2.8B	$2.4B	$2.2B	$1.9B	$1.4B	$1.1B	$1.1B	$903M	$666M	$573M	$367M	$185M
Gross Profit	$2.9B	$2.9B	$2.9B	$2.7B	$3.0B	$3.2B	$2.2B	$2.5B	$2.3B	$1.8B	$1.7B	$1.5B	$1.3B	$912M	$774M	$709M	$602M	$461M	$368M	$234M	$125M
Gross Margin %	67.1%	66.7%	65.4%	60.9%	64.8%	69.7%	68.0%	69.6%	69.0%	66.3%	69.5%	69.8%	69.7%	64.2%	67.3%	67.2%	66.6%	69.1%	64.1%	63.9%	67.8%
Operating Income (EBIT)	$919M	$864M	($833M)	($1.1B)	($4.2B)	($123M)	$393M	$985M	$883M	$606M	$587M	$613M	$515M	$134M	$201M	$199M	$212M	$126M	$80M	($301M)	$38M
Operating Margin %	20.9%	19.9%	-19.1%	-23.7%	-91.2%	-2.7%	12.1%	27.8%	26.5%	22.0%	24.5%	27.6%	27.7%	9.4%	17.5%	18.9%	23.4%	18.9%	14.0%	-82.1%	20.5%
Net Income	$853M	$850M	($1.2B)	($1.2B)	($4.4B)	$762M	$656M	$1.0B	$826M	$726M	$463M	$462M	$353M	$125M	$151M	$87M	$125M	$72M	$50M	($278M)	$40M
Net Margin %	19.4%	19.6%	-28.0%	-25.8%	-96.1%	16.8%	20.2%	28.3%	24.8%	26.4%	19.3%	20.8%	19.0%	8.8%	13.2%	8.2%	13.8%	10.8%	8.8%	-75.9%	21.6%
EBITDA	$1.4B	$1.5B	($725M)	($1.1B)	($3.8B)	$128M	$580M	$1.2B	$1.1B	$762M	$735M	$753M	$603M	$297M	$326M	$237M	$252M	$169M	$123M	$18M	$44M
Earnings Per Share (EPS)	$5.51	$5.45	$-7.69	$-7.35	$-28.05	$5.05	$4.43	$6.72	$5.54	$4.91	$3.13	$3.10	$2.37	$0.90	$1.13	$0.62	$0.87	$0.53	$0.38	$-2.57	$0.41
Shares Outstanding (M)	154M	156M	159M	158M	157M	151M	148M	149M	149M	148M	148M	149M	149M	140M	134M	139M	143M	137M	134M	108M	98M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ILMN Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$1.1B	$1.2B	$1.1B	$1.1B	$1.0B	$1.1B	$1.1B	$1.1B
Gross Profit	$721M	$778M	$732M	$717M	$685M	$728M	$745M	$721M
Gross Margin %	66.1%	67.1%	67.6%	67.8%	65.8%	65.9%	69.0%	64.8%
Operating Income (EBIT)	$209M	$257M	$231M	$222M	$184M	$202M	$741M	($1.6B)
Operating Margin %	19.2%	22.2%	21.3%	21.0%	17.7%	18.3%	68.6%	-147.2%
Net Income	$134M	$334M	$150M	$235M	$131M	$187M	$705M	($2.0B)
Net Margin %	12.3%	28.8%	13.9%	22.2%	12.6%	16.9%	65.3%	-178.8%
EBITDA	$250M	$471M	$312M	$399M	$253M	$283M	$826M	($1.9B)
Earnings Per Share (EPS)	$0.87	$2.17	$0.97	$1.50	$0.82	$1.17	$4.41	$-12.50
Shares Outstanding (M)	154M	154M	154M	157M	159M	160M	160M	159M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ILMN Free Cash Flow History

Cash flow	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$1.1B	$1.1B	$837M	$478M	$392M	$545M	$1.1B	$1.1B	$1.1B	$875M	$687M	$660M	$501M	$386M	$292M	$358M	$273M	$174M	$88M	$56M	$39M
Capital Expenditures (CapEx)	$139M	$148M	$128M	$195M	$286M	$208M	$189M	$209M	$296M	$312M	$271M	$143M	$142M	$91M	$81M	$80M	$56M	$55M	$96M	$24M	$15M
Free Cash Flow (FCF)	$989M	$931M	$709M	$283M	$106M	$337M	$891M	$842M	$846M	$563M	$416M	$516M	$359M	$296M	$211M	$279M	$216M	$119M	($8M)	$32M	$24M
FCF Margin %	22.5%	21.5%	16.2%	6.3%	2.3%	7.4%	27.5%	23.8%	25.4%	20.5%	17.3%	23.3%	19.3%	20.8%	18.4%	26.4%	23.9%	17.9%	-1.4%	8.7%	12.9%
Dividends Paid	—	—	—	—	$937M	$511M	—	—	$735M	$5M	$12M	$0M	$1.1B	$125M	$0M	$858M	$0M	$146M	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ILMN Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$289M	$321M	$284M	$234M	$240M	$364M	$316M	$80M
Capital Expenditures (CapEx)	$38M	$54M	$24M	$23M	$39M	$29M	$32M	$31M
Free Cash Flow (FCF)	$251M	$267M	$260M	$211M	$201M	$335M	$284M	$49M
FCF Margin %	23.0%	23.0%	24.0%	20.0%	19.3%	30.3%	26.3%	4.4%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ILMN Balance Sheet History

Balance sheet	2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$6.6B	$6.6B	$6.3B	$10.1B	$12.3B	$15.2B	$7.6B	$7.3B	$7.0B	$5.3B	$4.3B	$3.7B	$3.3B	$3.0B	$2.6B	$2.2B	$1.8B	$1.4B	$1.4B	$988M	$301M
Cash & Cash Equivalents	$1.1B	$1.4B	$1.1B	$1.0B	$2.0B	$1.2B	$1.8B	$2.0B	$1.1B	$1.2B	$735M	$769M	$636M	$712M	$434M	$303M	$249M	$145M	$327M	$175M	$38M
Total Liabilities	$3.9B	$3.9B	$3.9B	$4.4B	$5.7B	$4.5B	$2.9B	$2.7B	$3.1B	$2.3B	$2.0B	$1.8B	$1.9B	$1.5B	$1.2B	$1.1B	$641M	$566M	$529M	$576M	$53M
Total Debt (Short + Long-Term)	$2.1B	$2.1B	$2.1B	$1.6B	$2.8B	$1.8B	$1.2B	$1.2B	$2.0B	$1.2B	$1.0B	$1.1B	$1.3B	$869M	$842M	$844M	$390M	$390M	$400M	$400M	$0M
Total Shareholders' Equity	$2.7B	$2.7B	$2.4B	$5.7B	$6.6B	$10.7B	$4.7B	$4.6B	$3.8B	$2.8B	$2.3B	$1.8B	$1.5B	$1.5B	$1.3B	$1.1B	$1.2B	$864M	$849M	$412M	$247M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ILMN viewer.

Other Companies in DIAGNOSTICS & RESEARCH

NTRA · Natera Inc — $38 billion
GH · Guardant Health Inc — $20 billion
MEDP · Medpace Holdings Inc — $15 billion
ICLR · ICON PLC — $13 billion

← ILLU All stocks IMA →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.